Idenix hasn't found a court in the US friendly to their claim but perhaps Europe will be different. I don't think so but who knows. Gilead isn't a one trick pony like Idenix. I do wish that Gilead would lower their price on Solvadi and make it more accessible to more people but I guess they think that's what the market will bear. On the other hand, their treatment is cheaper than a liver transplant.
Down today apparently due to recall of 39000 vials of Atriplia HIV drug. Small amount of rubber particles found by Gilead and they notified FDA and did voluntary recall. Lot was manufactured in China but several other suppliers are available. It should recover from this quickly.
Inovio (INO) is at $2.75 per share. They've been working on DNA vaccines for awhile and use electroporation to deliver the vaccines. They've gotten some pretty good T-cell response. Just signed a deal with Roche. It's a stock you might research.
I agree with your posting. However, it indicates that Idix has senior party status. They did at one time but it's my understanding that was reversed and the senior status was awarded to Gilead indicating that they were indeed the first to file the patent. Anyway, I think Gilead will prevail in this lawsuit and will be able to take the lion's share of the Hep C market. Abbvie, et.al., have good drugs too and there will most likely be some pricing pressure. I still think investors should be looking more at Gilead's cancer drug pipeline. A phase III was recently halted because the results were too positive to deny all participants to receive the treatment. That's pretty impressive.
I have owned Gilead since it was in the low 40's. I don't know the final outcome of the issue with Idix but based on the fact that Gilead is now considered the senior in the lawsuit is very positive. Competition from Abbvie, J&J, Merck, and others is not new news. I like this companies pipeline in HIV, Hep C, and cancer and it's past record of bringing products to market in a very big way. I could care less what happens from day to day.
Originally Idix was given senior party status but that was reversed. Gilead now has senior party status which means that the folks at the Patent Office determined that Gilead filed the patent first. Anyway, Idix has tried to settle this without litigation but Gilead feels confident they are right and has preferred to let the courts settle this dispute. At best, Idix would get some sort of royalty but it looks to me like Gilead has the upper hand. Time will tell.
I can't predict the outcome of the litigation but in March of 2013 when the Patent folks changed their minds and made Gilead the "senior party" which means they determined that Gilead filed the patent first, I became a tad more confident that Gilead will prevail. Time will tell but lawsuits are not at all unusual in this world we live in.
I agree. Investors should not only focus on Gilead's HIV and Hep C market (and they are quite lucrative) but on the future of the cancer drugs they have in development. Hang in there if you can. I think this stock will be going higher.
I usually give only moderate attention to insider selling but the current, last 3 months of 2013, is puzzling as far as Gilead is concerned. I understand profit taking and estate planning but why would you sell such a big winner at the end of a year. If you sell in the beginning of the year you don't have to pay capital gains until April of the next year. And if you think, as I thought I did, that the approval of Sovaldi and the other drugs in their pipeline would lead to an explosion in their earnings, then why sell so many shares. Perhaps someone on this board knows a logical answer.